NorthSea Expands Leadership with Industry Veterans
Portfolio - People | Feb 21, 2025 | Ysios Capital
NorthSea Therapeutics, a private, late-stage clinical biotechnology company headquartered in Amsterdam, has announced significant additions to its leadership team. The company, known for developing treatments for metabolic, cholestatic, and fibrotic diseases, appointed Melissa Bradford-Klug as Chief Financial Officer and Chief Business Officer, and Sophie Jeannin as Chief Medical Officer. Bradford-Klug brings over two decades of strategic finance and business development experience, helping secure significant funding and guiding strategic partnerships. Her previous roles include leadership positions at Akari Therapeutics and other biotech firms. Jeannin, an accomplished physician, has deep expertise in clinical development and regulatory strategy, having guided programs to engage with global regulatory bodies like the FDA and EMA. NorthSea is backed by prominent investors such as Ysios Capital and Forbion Growth among others. The company looks forward to key clinical milestones with SEFA-1024 and Orziloben trials in the coming years.
Sectors
- Biotechnology
- Healthcare
- Pharmaceuticals
Geography
- Netherlands – NorthSea Therapeutics is headquartered in the Netherlands, and the article references its activities there.
- United States – The article mentions the presence of NorthSea Therapeutics in the US, highlighting its global reach.
Industry
- Biotechnology – The article focuses on NorthSea Therapeutics, a biotechnology company involved in developing novel therapies for metabolic, cholestatic, and fibrotic diseases.
- Healthcare – The appointment of executives with backgrounds in healthcare innovation, clinical trials, and the development of therapies highlights the article's relevance to the healthcare sector.
- Pharmaceuticals – The discussion of novel drug development strategies for diseases with unmet needs places this article within the pharmaceutical industry.
Financials
- $80M – NorthSea Therapeutics' Series C financing amount.
- 3Q 2025 – Expected date for topline data release from the SEFA-1024 Phase 2a clinical trial in SHTG.
- 1H 2026 – Expected interim data release from the Orziloben Phase 2a clinical trial in IFALD.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| NorthSea Therapeutics B.V. | Target company | Company | A private, late-stage clinical biotechnology company specializing in treatments for metabolic, cholestatic, and fibrotic diseases. |
| Ysios Capital | Private Equity firm/investor | Company | A private equity firm co-leading NorthSea's Series C financing. |
| Melissa Bradford-Klug | Chief Financial Officer and Chief Business Officer | Person | Newly appointed executive at NorthSea with a strong background in strategic finance and business development. |
| Sophie Jeannin | Chief Medical Officer | Person | Recently appointed CMO at NorthSea, expert in clinical development, and regulatory strategy for metabolic diseases. |
| Forbion Growth | Investor | Company | Co-led the Series C financing of NorthSea Therapeutics. |